Literature DB >> 29380622

Atropisomerism in medicinal chemistry: challenges and opportunities.

Sean T Toenjes1, Jeffrey L Gustafson1.   

Abstract

Atropisomerism is a dynamic type of axial chirality that is ubiquitous in medicinal chemistry. There are several examples of stable atropisomeric US FDA-approved drugs and experimental compounds, and in each case the atropisomers of these compounds possess drastically different biological activities. Rapidly interconverting atropisomerism is even more prevalent, and while such compounds are typically considered achiral, they bind their protein targets in an atroposelective fashion, with the nonrelevant atropisomer contributing little to the desired activities. It has been recently demonstrated that various properties of an interconverting atropisomer can be modulated through the synthesis of atropisomer stable and pure analogs. Herein we discuss examples of atropisomerism in drug discovery as well as challenges and opportunities moving forward.

Keywords:  atropisomer; chirality; drug discovery; kinase inhibitor; target selectivity

Mesh:

Substances:

Year:  2018        PMID: 29380622      PMCID: PMC5967358          DOI: 10.4155/fmc-2017-0152

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  74 in total

Review 1.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 2.  Nonbiaryl and Heterobiaryl Atropisomers: Molecular Templates with Promise for Atropselective Chemical Transformations.

Authors:  Elango Kumarasamy; Ramya Raghunathan; Mukund P Sibi; J Sivaguru
Journal:  Chem Rev       Date:  2015-09-28       Impact factor: 60.622

3.  Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor.

Authors:  Keith R Fandrick; Wenjie Li; Yongda Zhang; Wenjun Tang; Joe Gao; Sonia Rodriguez; Nitinchandra D Patel; Diana C Reeves; Jiang-Ping Wu; Sanjit Sanyal; Nina Gonnella; Bo Qu; Nizar Haddad; Jon C Lorenz; Kanwar Sidhu; June Wang; Shengli Ma; Nelu Grinberg; Heewon Lee; Youla Tsantrizos; Marc-André Poupart; Carl A Busacca; Nathan K Yee; Bruce Z Lu; Chris H Senanayake
Journal:  Angew Chem Int Ed Engl       Date:  2015-05-04       Impact factor: 15.336

Review 4.  The exploration of macrocycles for drug discovery--an underexploited structural class.

Authors:  Edward M Driggers; Stephen P Hale; Jinbo Lee; Nicholas K Terrett
Journal:  Nat Rev Drug Discov       Date:  2008-07       Impact factor: 84.694

Review 5.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

Review 6.  Biological stereoselectivity of atropisomeric natural products and drugs.

Authors:  Arie Zask; John Murphy; George A Ellestad
Journal:  Chirality       Date:  2013-05       Impact factor: 2.437

7.  Structure and chemical inhibition of the RET tyrosine kinase domain.

Authors:  Phillip P Knowles; Judith Murray-Rust; Svend Kjaer; Rizaldy P Scott; Sarah Hanrahan; Massimo Santoro; Carlos F Ibáñez; Neil Q McDonald
Journal:  J Biol Chem       Date:  2006-08-23       Impact factor: 5.157

8.  Targeted covalent drugs of the kinase family.

Authors:  Juswinder Singh; Russell C Petter; Arthur F Kluge
Journal:  Curr Opin Chem Biol       Date:  2010-07-06       Impact factor: 8.822

9.  Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Authors:  Flavio Solca; Goeran Dahl; Andreas Zoephel; Gerd Bader; Michael Sanderson; Christian Klein; Oliver Kraemer; Frank Himmelsbach; Eric Haaksma; Guenther R Adolf
Journal:  J Pharmacol Exp Ther       Date:  2012-08-10       Impact factor: 4.030

10.  Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

Authors:  Susan M Hanson; Elaine V Morlock; Kenneth A Satyshur; Cynthia Czajkowski
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

View more
  22 in total

1.  Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants.

Authors:  Sean T Toenjes; Valeria Garcia; Sean M Maddox; Gregory A Dawson; Maria A Ortiz; F Javier Piedrafita; Jeffrey L Gustafson
Journal:  ACS Chem Biol       Date:  2019-08-29       Impact factor: 5.100

2.  Towards a Catalytic Atroposelective Synthesis of Diaryl Ethers via C(sp 2)-H Alkylation Using Nitroalkanes.

Authors:  Andrew N Dinh; Ryan R Noorbehesht; Sean T Toenjes; Amy C Jackson; Mirza A Saputra; Sean M Maddox; Jeffrey L Gustafson
Journal:  Synlett       Date:  2018-07-31       Impact factor: 2.454

3.  Asymmetric Catalysis upon Helically Chiral Loratadine Analogues Unveils Enantiomer-Dependent Antihistamine Activity.

Authors:  Elizabeth A Stone; Kara J Cutrona; Scott J Miller
Journal:  J Am Chem Soc       Date:  2020-07-09       Impact factor: 15.419

4.  Enantioselective Synthesis of Pyrrolopyrimidine Scaffolds through Cation-Directed Nucleophilic Aromatic Substitution.

Authors:  Mariel M Cardenas; Sean T Toenjes; Christopher J Nalbandian; Jeffrey L Gustafson
Journal:  Org Lett       Date:  2018-03-21       Impact factor: 6.005

5.  Troponoid Atropisomerism: Studies on the Configurational Stability of Tropone-Amide Chiral Axes.

Authors:  Danielle R Hirsch; Anthony J Metrano; Elizabeth A Stone; Golo Storch; Scott J Miller; Ryan P Murelli
Journal:  Org Lett       Date:  2019-03-14       Impact factor: 6.005

6.  Atroposelective Desymmetrization of Resorcinol-Bearing Quinazolinones via Cu-Catalyzed C-O Bond Formation.

Authors:  Hyung Yoon; Alexandra Galls; Soren D Rozema; Scott J Miller
Journal:  Org Lett       Date:  2022-01-10       Impact factor: 6.005

7.  The Growing Importance of Chirality in 3D Chemical Space Exploration and Modern Drug Discovery Approaches for Hit-ID: Topical Innovations.

Authors:  Ilaria Proietti Silvestri; Paul J J Colbon
Journal:  ACS Med Chem Lett       Date:  2021-07-16       Impact factor: 4.632

Review 8.  Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.

Authors:  Brian A Lanman; Andrew T Parsons; Stephan G Zech
Journal:  Acc Chem Res       Date:  2022-09-30       Impact factor: 24.466

9.  Atropisomerism in the Pharmaceutically Relevant Realm.

Authors:  Mariami Basilaia; Matthew H Chen; Jim Secka; Jeffrey L Gustafson
Journal:  Acc Chem Res       Date:  2022-09-26       Impact factor: 24.466

10.  Catalytic Atroposelective Synthesis of N-Aryl Quinoid Compounds.

Authors:  Sagar D Vaidya; Sean T Toenjes; Nobuyuki Yamamoto; Sean M Maddox; Jeffrey L Gustafson
Journal:  J Am Chem Soc       Date:  2020-01-28       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.